KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Total Non-Current Liabilities (2016 - 2025)

Sarepta Therapeutics has reported Total Non-Current Liabilities over the past 16 years, most recently at $2.2 billion for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 7.56% year-over-year to $2.2 billion; the TTM value through Dec 2025 reached $2.2 billion, down 7.56%, while the annual FY2025 figure was $2.2 billion, 7.56% down from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $2.2 billion at Sarepta Therapeutics, up from $2.2 billion in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $2.7 billion in Q4 2022 and troughed at $2.1 billion in Q3 2021.
  • A 5-year average of $2.3 billion and a median of $2.3 billion in 2025 define the central range for Total Non-Current Liabilities.
  • Biggest five-year swings in Total Non-Current Liabilities: rose 25.1% in 2022 and later fell 14.18% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $2.2 billion in 2021, then increased by 24.36% to $2.7 billion in 2022, then dropped by 12.54% to $2.4 billion in 2023, then rose by 0.88% to $2.4 billion in 2024, then decreased by 7.56% to $2.2 billion in 2025.
  • Business Quant data shows Total Non-Current Liabilities for SRPT at $2.2 billion in Q4 2025, $2.2 billion in Q3 2025, and $2.3 billion in Q2 2025.